Cushing's Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer.
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Diagnosis and complications of Cushing's syndrome: a consensus statement.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)
- Q4 2026An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
- Q3 2027A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome
- Q4 2028Phase II Prospective Evaluation of Desmopressin Stimulation Test Performance in ACTH-dependent Cushing s Syndrome
Clinical MilestonesViewHide
- 2026-07-06Phase II Prospective Evaluation of Desmopressin Stimulation Test Performance in ACTH-dependent Cushing s SyndromeResults expected Q4 2028
- 2026-06-04A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)Results expected Q4 2026
- 2026-04-21An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing SyndromeResults expected Q4 2026
- 2026-03-27A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's SyndromeResults expected Q3 2027
- 2026-07-06ClinicalPhase II Prospective Evaluation of Desmopressin Stimulation Test Performance in ACTH-dependent Cushing s SyndromeResults expected Q4 2028
- 2026-06-04ClinicalA Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)Results expected Q4 2026
- 2026-04-21ClinicalAn Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing SyndromeResults expected Q4 2026
- 2026-03-27ClinicalA Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's SyndromeResults expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults. (2020)
Accelerated approval — Ketoconazole Esteve is indicated for the treatment of endogenous Cushing’s syndrome in ad… (2014)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Cushing Syndrome4
- Adenoma1
- Adrenocortical Adenoma1
- Antioxidants1
- Cardiovascular Diseases1
- Diabetes Mellitus1
- Frailty1
- Metabolic Syndrome1
Leading journals5
- The Journal of clinical endocrinology and metabolism2
- Endocrinology and metabolism (Seoul, Korea)1
- European journal of endocrinology1
- Frontiers in endocrinology1
- Journal of internal medicine1
Leading researchers8
- Findling JW2
- Newell-Price J2
- Nieman LK2
- Achenbach SJ1
- Ambroziak U1
- Angeli A1
- Arnaldi G1
- Athimulam S1
Affiliations (unnormalised)6
- Chungnam National University College of Medicine1
- Department of Veterinary Clinical Sciences1
- Division of Clinical Trials and Biostatistics1
- Erasmus MC University Medical Center Rotterdam1
- Evangelismos Hospital1
- General Hospital Koprivnica1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Cushing syndrome is a condition caused by prolonged exposure to excess cortisol or other glucocorticoids from endogenous or exogenous sources. It is characterized by features such as upper body obesity, osteoporosis, hypertension, diabetes mellitus, hirsutism, amenorrhea, and excess body fluid. Endogenous Cushing syndrome, also called spontaneous hypercortisolism, is divided into ACTH-dependent and ACTH-independent forms.
The syndrome results from prolonged exposure to excess glucocorticoids, either from outside the body or from endogenous overproduction. The supplied grounding specifically distinguishes endogenous disease into ACTH-dependent causes and ACTH-independent causes. No more specific etiologies are supported in the grounding provided.
The core biological mechanism is chronic glucocorticoid excess, which drives the clinical syndrome and its metabolic complications. The literature grounding links Cushing syndrome to metabolic dysregulation, cardiometabolic deterioration, and oxidative stress associated with adrenal hormone imbalance. Endogenous disease is mechanistically grouped into ACTH-dependent and ACTH-independent hypercortisolism.
The grounding supports prolonged exposure to glucocorticoids as the main risk factor for developing Cushing syndrome. It also supports endogenous ACTH-dependent or ACTH-independent hypercortisolism as underlying risk contexts. No additional demographic or clinical risk factors are supported by the supplied material.
The supplied review and guideline abstracts support diagnostic evaluation and assessment of complications as central management themes. They do not provide treatment modalities beyond diagnosis-focused guidance, so no standard therapeutic class can be stated from the grounding alone. Accordingly, this field is null.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.